O-102 Results of a phase 2 study of the oral tyrosine kinase inhibitor (TKI): axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)

S. Chan; A. Stopeck; A.A. Joy; S. Verma; A. Lluch; K.F. Liau; S. Kim; P. Bycott; D. Soulieres; H.S. Rugo

首页> 外文期刊>European Journal of Cancer Supplements >O-102 Results of a phase 2 study of the oral tyrosine kinase inhibitor (TKI): axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)

【24h】

O-102 Results of a phase 2 study of the oral tyrosine kinase inhibitor (TKI): axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)

机译：O-102口服酪氨酸激酶抑制剂（TKI）：阿昔替尼（AG-013736; AG）与多西他赛（DOC）联合DOC加安慰剂（PL）联合用于一线转移性乳腺癌（MBC）的2期研究结果）

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第3期|共1页
作者
S. Chan; A. Stopeck; A.A. Joy; S. Verma; A. Lluch; K.F. Liau; S. Kim; P. Bycott; D. Soulieres; H.S. Rugo;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 2103 ORAL A randomized, double-blind phase 2 study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC) [J] . S.Chan, A.Stopeck, A.A.Joy, European Journal of Cancer Supplements . 2007,第4期

机译：2103口服口服酪氨酸激酶抑制剂（TKI）阿西替尼（AG-013736; AG）联合多西他赛（DOC）与DOC加安慰剂（PL）联合用于一线转移性乳腺癌的随机双盲2期研究（ MBC）
2. Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer. [J] . Rugo HS, Stopeck AT, Joy AA, Journal of Clinical Oncology . 2011,第18期

机译：阿西替尼加多西他赛与多西他赛加安慰剂在转移性乳腺癌患者中的随机，安慰剂对照，双盲，II期研究。
3. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. [J] . Miles DW, Chan A, Dirix LY, Journal of Clinical Oncology . 2010,第20期

机译：贝伐单抗加多西他赛与安慰剂加多西他赛比较用于人表皮生长因子受体2阴性转移性乳腺癌的一线治疗的III期研究。
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. Development of pharmacokinetic-directed dosing of docetaxel in combination with a tyrosine kinase inhibitor for optimization of cancer drug therapy [D] . Pierce, Erica Lynn Bradshaw 2007

机译：与多西他赛结合酪氨酸激酶抑制剂的药代动力学指导剂量的开发，以优化癌症药物治疗
6. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer [O] . F Ciardiello, T Troiani, F Caputo, 2006

机译：吉非替尼联合多西紫杉醇作为转移性乳腺癌的一线治疗的II期研究
7. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. [O] . Miles David, Chan Arlene, Dirix Luc, 2010

机译：贝伐单抗加多西他赛与安慰剂加多西他赛比较用于人表皮生长因子受体2阴性转移性乳腺癌的一线治疗的III期研究。

O-102 Results of a phase 2 study of the oral tyrosine kinase inhibitor (TKI): axitinib (AG-013736; AG) in combination with docetaxel (DOC) vs DOC plus placebo (PL) in first-line metastatic breast cancer (MBC)

著录项

相似文献

相关主题

期刊订阅